Oric Pharmaceuticals price target lowered to $19 from $20 at Wells Fargo

Wells Fargo lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $19 from $20 and keeps an Overweight rating on the shares. The firm thought the ORIC-944 update was incremental, as expected, demonstrating fairly consistent activity and good safety. Wells remains positive on this program ahead of a more robust update in Q1 2026 which is the key catalyst, in its view.